Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Arens

Showing results (81-90 of 82) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 82 results.
Trials|June 17, 2025
[<sup>18</sup>F]FET PET-Guided management of pseudoprogression in glioblastoma (FET POPPING): the study protocol for a diagnostic randomized clinical trialV J Ruijters, T J Snijders, J A J van der Pol, et al.
Haematologica|April 16, 2026
Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL studyMarie José Kersten, Martin Dreyling, Kim M Linton, et al.
Pageof 9

Showing results (81-90 of 82) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 82 results.
Trials|June 17, 2025
[<sup>18</sup>F]FET PET-Guided management of pseudoprogression in glioblastoma (FET POPPING): the study protocol for a diagnostic randomized clinical trialV J Ruijters, T J Snijders, J A J van der Pol, et al.
Haematologica|April 16, 2026
Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL studyMarie José Kersten, Martin Dreyling, Kim M Linton, et al.
Pageof 9